Grace Quigley
Manager External Comms •
Sydney
Media release: Clayton Utz advises NYSE-listed Solventum Corp on the USD$4.0 billion sale of its purification and filtration business to Thermo Fisher Scientific Inc
1 minute
Clayton Utz advised US-based healthcare company Solventum Corp (NYSE: SOLV) on the Australian aspects of the sale of its purification and filtration (P&F) business to Thermo Fisher Scientific Inc. (NYSE: TMO) for USD$4.0 billion (AUD$6.1 billion) in cash.
The sale of the P&F business involved more than 30 jurisdictions and was led by Solventum's US counsel, Cleary Gottlieb Steen & Hamilton LLP.
Clayton Utz corporate partner Rory Moriarty, alongside special counsel Samuel Pullin and lawyer Alana Dunn, acted as Solventum's Australian counsel. The firm's multidisciplinary team included key support from Real Estate partner Eva Oraham, special counsel Ben Pierce and lawyer Emil Obaid, Tax partner Peter Feros and senior associate Alex Melara, as well as Workplace Relations partner Amanda Lyras and senior associate Nicole Flax.
Get in touch
Disclaimer
Clayton Utz communications are intended to provide commentary and general information. They should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this communication. Persons listed may not be admitted in all States and Territories.